drugset / Trial / NCT05080049

Erythropoietin to Improve Critical Care Patient Outcomes

NCT05080049

Phase 3 Unknown 42 enrolled University Hospital, Angers
RandomizedParallel-groupTriple-blindTreatment

Summary

Recently, the french societies for critical care (SFAR and SRLF) produced guidelines for anemia treatment in critically ill patients that recommend the use of erythropoietin (EPO) in these patients, but the european society (ESICM) recommended against the use of EPO in this patients, despite recent meta analysis showing a lower mortality in patients treated with EPO. Nevertheless, RCT on EPO in the ICU are quite all, new data are thus needed. Before conducting a large study on EPO in anemic patients in the ICU, we propose to cinduct a feasability RCT to evaluate the feasability of such a study.

Timeline

Start
2022-01-28
Primary completion
2022-09-02
Completion
2022-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject epoetin alfa Protein / enzyme biologic 40000 iu Subcutaneous

Indications